Thermo Fisher stock still cheap despite outperformance, Barron’s says

Thermo Fisher doubled its earnings during the pandemic but now trades more cheaply than it did at the start of 2020, even as sales hit new records, Teresa Rivas writes in this week’s edition of Barron’s. As the pandemic fades, earnings have dipped, taking the stock with them. But the slump shouldn’t last long, the author says. The shares also look appealing in the light of recent market turmoil: Although Thermo Fisher is often classified as a growth stock, it enjoys steady recurring revenue among loyal customers that often are doing intricate research and development. Reference Link